RESEARCH ARTICLE

A Cost Analysis of Hospitalizations for Infections Related to Injection Drug Use at a County Safety-Net Hospital in Miami, Florida

Hansel Tookes1*, Chanelle Diaz2*, Hua Li3, Rafi Khalid4, Susanne Doblecki-Lewis5

1 Department of Internal Medicine, Jackson Memorial Hospital, Miami, Florida, United States of America, 2 Department of Medical Education, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 3 Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 4 Department of Jackson Health System Research, Jackson Memorial Hospital, Miami, Florida, United States of America, 5 Department of Internal Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, United States of America

* These authors contributed equally to this work.
hetookes@med.miami.edu

Abstract

Background
Infections related to injection drug use are common. Harm reduction strategies such as syringe exchange programs and skin care clinics aim to prevent these infections in injection drug users (IDUs). Syringe exchange programs are currently prohibited by law in Florida. The goal of this study was to estimate the mortality and cost of injection drug use-related bacterial infections over a 12-month period to the county safety-net hospital in Miami, Florida. Additionally, the prevalence of HIV and hepatitis C virus among this cohort of hospitalized IDUs was estimated.

Methods and Findings
IDUs discharged from Jackson Memorial Hospital were identified using the International Classification of Diseases, Ninth Revision, codes for illicit drug abuse and endocarditis, bacteremia or sepsis, osteomyelitis and skin and soft tissue infections (SSTIs). 349 IDUs were identified for chart abstraction and 92% were either uninsured or had publicly funded insurance. The total cost for treatment for injection drug use-related infections to Jackson Memorial Hospital over the 12-month period was $11.4 million.

Conclusions
Injection drug use-related bacterial infections represent a significant morbidity for IDUs in Miami-Dade County and a substantial financial cost to the county hospital. Strategies aimed at reducing risk of infections associated with injection drug use could decrease morbidity and the cost associated with these common, yet preventable infections.
Introduction

Miami-Dade County ranks first in the United States in new HIV infections [1]. Estimates of HIV prevalence among injection drug users (IDUs) in Miami range from 14% to 23% [2,3]. In 2011 Florida House Bill 7075 was signed into law, giving the State legal authority to close “pill mills” or pain management clinics and enacting stricter medical and pharmacy regulations of prescription opiates starting in July 2012. Heroin-related deaths in Miami increased from 15 to an estimated 36 from 2011 to 2013, and primary treatment admissions for heroin also increased from 227 to 294 during that time [4].

IDUs without access to sterile injection equipment commonly experience skin and soft tissue infections (SSTIs) such as cellulitis and abscesses [5–8]. One study of IDUs in San Francisco found that nearly one-third had experienced SSTIs [7]. SSTIs are associated with inexperience [9], subcutaneous or intramuscular injection known as “skin popping” [7], “speed balling” or the injection of heroin plus cocaine [10,11], and black tar heroin [12,13]. Similarly, the drug of choice may increase the frequency of injection and thereby the risk of infection; for example, IDUs injecting cocaine may inject more than 20 times per day [14,15]. The use of dirty needles and failure to disinfect the skin before injection can also increase the risk of infections [9,10].

In addition to SSTIs, IDUs are frequently hospitalized for complications of bacteremia, which results from inadvertently introducing bacteria into the bloodstream, and can lead to sepsis, endocarditis, and hematogenous osteomyelitis [16,17]. Musculoskeletal infections, such as osteomyelitis, can result from hematogenous spread without a related SSTI [9]. Infective endocarditis is an increasingly common consequence of injection drug use that requires hospitalization for intravenous antibiotics, and in severe cases, cardiac surgery to replace the infected valves [18–20]. Infective endocarditis may be complicated by septic embolization to the lungs, central nervous system, spleen, and other organs [21,22]. These complications can lead to lengthy hospital stays and are associated with a significant mortality risk.

The high incidence of skin and soft tissue infections among IDUs has costly implications for cities with large IDU populations. Studies from urban public hospitals demonstrate that SSTIs are one of the most common reasons for seeking emergency department and inpatient treatment by IDUs, and can comprise a significant proportion of emergency department visits [5,23–25]. Takashi et al. estimated that there were 106,126 hospitalizations for injection drug use-related SSTIs in the US from 1998 to 2001 with an estimated annual nationwide total cost of $193.8 million [26]. The authors found that most IDUs hospitalized with SSTIs were uninsured or relied on Medicare or Medicaid [26]. IDUs with SSTIs tended to have longer and thereby more costly hospital stays compared with other hospitalized patients with an overall cost per hospitalization of $4,449 [26].

This study sought to determine the morbidity, mortality, and cost of hospitalizations for bacterial infections related to injection drug use at the Miami-Dade County safety-net hospital, Jackson Memorial Hospital, over a 12-month period. Additionally, the prevalence of HIV and hepatitis C virus among IDUs admitted to the hospital during the study period was estimated. The data presented will provide a comprehensive estimate of the financial impact of injection drug use-related hospitalizations at a single hospital in Miami-Dade County.

Methods

Study design

We conducted a retrospective chart review of patients hospitalized for injection drug use-related infections at the county safety-net hospital, in Miami, Florida during a 12-month period, from July 1, 2013 to June 30, 2014.
Ethics Statement
The study was approved by the University of Miami Miller School of Medicine Institutional Review Board and the Jackson Health System Clinical Research Review Committee. Informed consent was not obtained from participants and a consent waiver was granted. The data were de-identified prior to analysis.

Study Setting
Jackson Memorial Hospital is a nonprofit academic medical center and the third largest public hospital in the United States with 1502 licensed beds and an estimated 49,509 annual discharges. It has served as the Miami-Dade County safety-net hospital for nearly a century. The hospital is supported by the taxpayers of Miami-Dade County and governed by the Public Health Trust Board of Trustees.

Data Collection
We queried the Jackson Memorial Hospital electronic discharge and billing records from July 1, 2013 to June 30, 2014 for injection drug use-related infections in all patients aged 18–65 years. We searched all diagnosis fields in the discharge record database. Discharges included both emergency department discharges and inpatient discharges. Injection drug use-related infection was defined as any discharge over the 12-month period from the inpatient services or emergency department with diagnoses of opiate, cocaine, amphetamine or sedative dependence/abuse and diagnoses of endocarditis, bacteremia/sepsis, osteomyelitis, abscesses or cellulitis. The International Classification of Diseases, Ninth Revision (ICD-9) codes used to identify an injection drug use-related infection are described below. The corresponding medical records were then abstracted for demographic information, length of stay, insurance status, discharge status, and charges related to the services received. HIV and hepatitis C status were also recorded. Specifically, the discharge records for all emergency department visits and inpatient hospitalizations were queried for drug abuse AND infection AND hospitalization between July 1, 2013 and June 30, 2014 AND age 18–65. Drug abuse included opiates OR cocaine OR amphetamines OR sedatives OR other. Infection included endocarditis OR bacteremia/sepsis OR osteomyelitis OR skin/soft tissue infection.

Definitions
Although the ICD-9 does not explicitly code for injection drug use, we employed an algorithm to identify IDUs using hospital billing records similar to those reported in the literature [5,23,26–28]. Inclusion in the study cohort as a patient with an injection drug use-related infection was based on a combination of ICD-9 codes for illicit drug abuse and medically related infections (Table 1). Patients aged 18–65 were included in the study to increase the specificity of the algorithm. HIV status was queried with ICD-9 codes 042, 079.53, 795.71 and V08. Hepatitis C infection was determined with codes 070.41, 070.44, 070.51, 070.54, V02.62.

Analysis
Descriptive statistics and frequency distributions for demographic, insurance status, infection diagnoses, drug abuse diagnoses, and hospital use variables were generated. Hospital use variables included discharge status and the corresponding charges for each hospitalization. Categorical data were described with numbers and percentages. Continuous variables were reported with median and interquartile range (IQR). A Euler diagram was constructed using
Table 1. ICD-9 codes used to define injection drug use-related infections.

| Diagnoses                      | ICD-9 codes                        |
|--------------------------------|------------------------------------|
| Drug abuse diagnoses          |                                    |
| Opiates                        | E850.0, E850.2, 304.00–304.03, 304.70–304.73, 305.50–305.53, 965.01, 965.09 |
| Cocaine                        | 304.21–304.23, 305.60–305.63, 970.81 |
| Amphetamines                   | 304.41–304.43, 305.71–305.73, 969.72 |
| Sedatives                      | 305.40–305.43                        |
| Other                          | 304.60–304.63, 304.80–304.83, 304.90–304.93, 305.90–305.93, 648.33, 648.34 |
| Infections                     |                                    |
| Endocarditis                   | 112.81, 421.0, 421.1, 421.9, 424.0–424.3, 424.90, 424.91, 424.99 |
| Bacteremia or Sepsis           | 038.0, 038.10–038.12, 038.19, 038.2, 038.3, 038.40–038.44, 038.49, 038.8, 038.9, 415.12, 422.92, 449, 785.52, 790.7, 995.90–995.92 |
| Osteomyelitis                  | 730.00–730.29, 730.90–730.99          |
| Skin or soft tissue infections | 040.0, 324.0, 324.1, 324.9, 326, 567.22, 567.31, 567.38, 569.5, 572.0, 590.1, 681.00–681.02, 681.10, 681.11, 681.9, 682.0–682.9, 709.8, 728.86, 723.6, 729.30, 729.39, 785.4 |

Hospitalizations for injection drug use-related infections were defined as having one or more drug abuse diagnoses with one or more infection diagnoses.

doi:10.1371/journal.pone.0129360.t001

EulerAPE version 3.0 to show the relationship between the observed frequencies of infectious diagnoses and respective cost[29]

Hospital charges data were analyzed to evaluate for the potential association of the different types of infections (endocarditis, bacteremia/sepsis, osteomyelitis, and skin and soft tissue infection) with an increased or decreased cost of hospitalization within the cohort. Patients with multiple infections were adjudicated prior to analysis based on the review of their medical records. The principal infection was determined in a hierarchical order based on clinical severity in the following order: endocarditis, bacteremia/sepsis, osteomyelitis, or SSTI. The Wilcoxon rank sums test was used to report a p value for the associations between specific infections and the respective total charges using a 2-tailed t test. In comparing adjusted mean charges between the different infection types, several linear regression models were applied with log-transformed outcomes. The models were adjusted for the presence of concomitant infections. To assess the potential impact of insurance status, age, HIV status, and opiate vs. non-opiate drug abuse on the relationship between bacterial infections and charges, the impact of forcing these variables into the multivariable model of charges was evaluated. Adjusted geometric means of the charges and their 95% confidence intervals were calculated. All analyses were completed using SAS Version 9.2 (SAS Institute Inc., Cary, NC).

The charges based on insurance status (county/uninsured, Medicare, Medicaid, private insurance) were reported. The cost over the 12-month period was estimated using the cost-to-charge ratio of 32% for Jackson Memorial Hospital, according to the most recent publicly filed facility profile. [30]

Results

Demographics

Demographics are presented in Table 2. Over the 12-month period there were 349 IDUs hospitalized, with a total of 423 admissions at Jackson Memorial Hospital for injection drug-use related infections. Seventy-one percent (n = 248) were male, 52% (n = 180) were white, and
41% (n = 142) were black. The relatively small percentage of Hispanic ethnicity reported in patients in the cohort (6%) compared to the population of Miami-Dade County (65.6%) is due to lack of consistent coding of this category by hospital admitting staff[31]The median age was 47 with an interquartile range (IQR) of 34, 54.

Only 8% (n = 27) of IDUs had private insurance. State-funded Medicaid programs were billed for 41% (n = 142) of patients. Federally-funded Medicare was billed for 15% (n = 54) of patients. Of the IDUs in the cohort, 36% (n = 126) were uninsured. Care for indigent patients at Jackson Memorial Hospital is supported by the taxpayers of Miami-Dade County via a 0.5% sales tax levied since 1991 for the Public Health Trust. Seventeen patients (5%) died during the hospital stay as determined by a discharge status of “expired.”

### Infections and Drug Abuse

Table 3 presents the frequencies of different infections and drug abuse within the cohort. The majority of the IDUs hospitalized for injection drug use-related infections had SSTIs (64%) resulting from direct inoculation of soft tissues with unsterile injection equipment. Serious infections such as endocarditis and bacteremia/sepsis were reported in 13% and 38% of IDUs, respectively. Osteomyelitis was diagnosed in 10% of the cohort. These infections were not mutually exclusive and 131 of the 349 IDUs in the cohort had multiple infections. Fig 1A shows the overlap of infectious diagnoses within the patients. The seroprevalence of HIV in the IDUs was 17%. Hepatitis C was reported in 15% of patients.

Thirty-seven percent of the cohort had opiate abuse diagnosed in discharge records. The majority of IDUs in the study had cocaine abuse diagnosed (59%). Amphetamines and sedatives were less common (3% and 2%, respectively). A substantial proportion of patients had
unspecified or other drug abuse reported (27%). Seventy-seven percent of IDUs had only one substance of abuse in their discharge diagnoses.

Charges for Hospitalizations

Table 4 shows the total charges for IDU-related hospitalizations during the 12-month period and their breakdown per insurance status. The median charge (IQR) for hospitalization for injection drug use-related infection was $39,896 ($14,158-$104,912). The majority of charges were billed to state-funded Medicaid programs ($18,375,845). Miami-Dade County taxpayer funded indigent care was charged $7,094,895 over the 12-month period. Medicare, a federally funded program, was charged $4,702,008. $5,464,512 was billed to private insurers. Accounting for an average cost to charge ratio for Jackson Memorial Hospital, the total cost to the hospital for services rendered for treating injection drug use-related infections from July 1, 2013 to June 30, 2014 was $11,403,923.

Specific infections were associated with higher charges for hospitalization according to the 2-tailed Wilcoxon Rank Sums test (Table 5). The adjusted mean charge for IDUs with endocarditis was $180,314 versus $71,581 for those without endocarditis (p<0.0001). Likewise, bacteremia/sepsis and osteomyelitis were associated with higher charges (p<0.0001 and p<0.0001, respectively). SSTIs were the only type of infection associated with decreased adjusted mean charges for hospitalization ($100,497 vs $128,432 in IDUs without SSTIs, p<0.0001). When age, HIV status, insurance status and opiate versus non-opiate drug abuse were added to the multivariable model, there was no significant effect on the association between the different types of infection and charges. Charges for the different bacterial infections are shown in Fig 1B.

Discussion

This study identified a cohort of 349 IDUs with preventable bacterial infections that resulted in admissions to the county safety net hospital in Miami during a 12-month period. These
hospitalizations resulted in $11.4 million in healthcare expenses and 17 deaths. The vast majority of hospitalized IDUs (92%) were either uninsured or relied on publicly funded insurers such as county, state and federal programs. While it is customary for hospitals to bill in excess of expected payment for services rendered based on pre-negotiated reimbursement rates, Florida Medicaid was billed $18.4 million over the study period for injection drug use-related infections. While the number of injection drug use-related overdoses and deaths are one measure of the health impact of drug abuse, this analysis demonstrates that these numbers reflect only a portion of the morbidity, mortality, and cost associated with this high risk behavior.

SSTIs were reported in a majority of the patients in our study. Patients who only had an SSTI had a decreased cost of hospitalization compared with those experiencing other infectious complications, suggesting that earlier diagnosis and treatment of abscesses and cellulitis could lead to cost savings. Studies from urban public hospitals demonstrate that SSTIs are one of the most common reasons for seeking emergency department and inpatient treatment by IDUs, and can burden the system by comprising a significant proportion of ED visits [5,23–25]. Complications of SSTIs such as osteomyelitis, necrotizing fasciitis, and sepsis often require surgical intervention with incision and drainage, debridement, antibiotics and prolonged

Table 4. Total charges for hospitalizations of IDUs for infections at Jackson Memorial Hospital.

| Insurance Status       | Total       | Median | IQR   | Total       | Median | IQR   |
|------------------------|-------------|--------|-------|-------------|--------|-------|
| IDU cohort             | $35,637,260 | $39,896| $14,158| $11,403,923 |        |       |
| County or uninsured    | $7,094,895  | $18,396| $4,058| $49,987     |        |       |
| Medicaid               | $18,375,845 | $68,209| $24,459| $153,392    |        |       |
| Medicare               | $4,702,008  | $56,872| $27,291| $119,411    |        |       |
| Private                | $5,464,512  | $29,010| $10,580| $100,812    |        |       |

doi:10.1371/journal.pone.0129360.t004

doi:10.1371/journal.pone.0129360.g001
hospitalization [32–36]. A study conducted at Seattle’s county hospital found that 40% of IDUs who sought ED care for an SSTI were admitted to the hospital. Of those IDUs admitted, 25% required operating room incision and drainage [37]. Similarly, a population-based study found that SSTIs were the leading cause of all non-psychiatric hospital admissions at San Francisco General Hospital from 1999–2000, resulting in $9.9 million in inpatient charges [5]. In response, San Francisco established a skin care clinic and reported that early intervention to prevent SSTIs saved San Francisco General Hospital $8,765,200 in its first year of implementation [38].

Economic modeling of syringe exchange programs for prevention of HIV infection has generally found this strategy to be cost-effective and frequently cost-saving [39–43]. Given the substantial cost of severe bacterial infections related to injection drug use, estimates that consider only the cost and health impact of HIV and hepatitis C infection likely underestimate the potential benefit of these programs. In the 2013 and 2014 Florida Legislative Sessions a bill was presented to establish a pilot syringe exchange program in Miami-Dade County. According to Florida Department of Health projections, the annual cost to operate the syringe exchange program would be $202,451 [44]. With median charges of $39,896 for each member of the cohort, the syringe exchange program would cost less than acute bacterial infections of only 6 IDUs (1.7% of the cohort). Other mitigation strategies, including multidisciplinary methadone treatment and skin care clinics, have demonstrated efficacy in reduction of hospitalization for skin and soft tissue infections at minimal comparative cost [38]. A syringe exchange program in Miami-Dade would also present an opportunity to impact the incidence of HIV in Miami-Dade County, which remains the highest nationwide [1]. In 2014, a bill analysis concluded that if 10% of the HIV infections recorded among IDUs in Miami-Dade County had been prevented, the State of Florida would have saved approximately $124 million [45].

There are several limitations to this study. Because the ICD-9 does not have a specific diagnosis code for injection drug use, the study relied on combinations of ICD-9 codes for drug abuse and infectious consequences, which could have resulted in misclassification bias. The study algorithm is similar to methods previously reported in the literature for the identification of injection drug use-related complications. Additionally, the number of infections associated with drug abuse is likely underestimated due to inconsistent documentation of drug abuse or use of the corresponding codes by physicians and other coding staff. Specific diagnoses such as hepatitis C infection that did not directly relate to the current admission could have been significantly under-reported. Additionally, due to stigma associated with injection drug use, some patients may not have reported drug abuse, leading to further underestimation. Furthermore, this study only reports injection drug use-related hospitalizations at one hospital in Miami-
Dade County and likely underestimates the countywide financial burden of these infections. Similar results are likely seen in other hospitals in Miami-Dade County serving the urban poor population. In other cities without syringe exchange programs and a large IDU population, a high economic burden of infections related to injection drug use would be expected at safety net hospitals.

We acknowledge that hospital charges based on insurance status is not equivalent to the cost of care as the hospital negotiates a different average cost-to-charge ratio for each insurer. However, we were able to estimate total cost by using the most recently reported average cost-to-charge ratio for Jackson Memorial Hospital.

Despite these limitations, this study adds to recent reports of substantial morbidity, mortality, and expense related to complications of the injection drug use and heroin epidemic in South Florida in the absence of any harm reduction programs [4]. This epidemic is highlighted by a 2012 study that compared the syringe disposal practices of IDUs in Miami to those in San Francisco, where four legal syringe exchange programs operate. The study revealed that Miami had eight times the number of used syringes improperly discarded in public, even though IDUs in San Francisco possessed and therefore disposed of significantly more syringes over a similar period of time [46]. While this study is not a formal cost-effectiveness analysis, costs associated with acute bacterial infections including cellulitis, osteomyelitis, sepsis, and endocarditis are substantial, and prevention of these infections would add to the cost-effectiveness of syringe exchange programs already demonstrated in other modeling studies focusing on HIV prevention. Cities such as Miami may benefit from harm reduction strategies like syringe exchange to reduce the number acute bacterial infections related to injection drug use as well as HIV and hepatitis C infections, and ultimately mitigate the health and economic burdens of these preventable infections.

Supporting Information
S1 Dataset. De-identified Dataset.
(XLSX)

Acknowledgments
We would like to thank the Infectious Diseases Society of America Medical Scholars Program and the Jackson Memorial Hospital Department of Internal Medicine Resident Scholarly Activity Program for funding this study. We would also like to thank Jonathan Robinson for data collection. Finally we would like to thank Jose Szapocznik, Stephen Symes, Leonardo Tamariz and Tanya Zakrison for their individual contributions to the study.

Author Contributions
Conceived and designed the experiments: HT CD SD. Performed the experiments: HT CD SD RK. Analyzed the data: HT CD SD HL. Wrote the paper: HT CD SD.

References
1. Centers for Disease Control and Prevention (CDC). HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2012; vol. 24. Published November 2014. http://www.cdc.gov/hiv/library/reports/surveillance/ Accessed 2015 Feb 18.
2. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992–2002. J Urban Health. 2009; 86: 132–154. doi: 10.1007/s11524-008-9328-1 PMID: 19015995
3. Broz D, Weinert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014; 63: 1–51. PMID: 25522191

4. Hall JN. Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2014. National Institute on Drug Abuse (NIDA). 2014; 6.

5. Centers for Disease Control and Prevention (CDC). Soft tissue infections among injection drug users—San Francisco, California, 1996–2000. MMWR Morb Mortal Wkly Rep. 2001; 50: 381–384. PMID: 11465906

6. Simmen HP, Giovannoni P, Battaglia H, Wust J, Meyer VE. Soft tissue infections of the upper extremities with special consideration of abscesses in parenteral drug abusers. A prospective study. J Hand Surg Br. 1995; 20: 797–800. PMID: 8770744

7. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000; 30: 579–581. PMID: 10722447

8. Lloyd-Smith E, Kerr T, Hogg RS, Li K, Montaner JS, Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J. 2005; 2: 24. PMID: 16281979

9. Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005; 353: 1945–1954. PMID: 16267325

10. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001; 33: 35–40. PMID: 11389492

11. Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am J Drug Alcohol Abuse. 2010; 36: 92–97. doi: 10.3109/00952991003592311

12. Kimura AC, Higa JI, Levin RM, Simpson G, Vargas Y, Vugia DJ. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis. 2004; 38: e87–91. PMID: 15127359

13. Lonergan S, Rodriguez RM, Schaulis M, Navaran P. A case series of patients with black tar heroin-associated necrotizing fasciitis. J Emerg Med. 2004; 26: 47–50. PMID: 14751477

14. Hyshka E, Strathdee S, Wood E, Kerr T. Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research. Int J Drug Policy. 2012; 23: 261–270. doi: 10.1016/j.drugpo.2012.03.006 PMID: 22579215

15. Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008; 8: 405-408. doi:10.1186/1471-2458-8-405

16. Marks M, Pollock E, Armstrong M, Morris-Jones S, Kidd M, Gothard P, et al. Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London Teaching Hospital. J Infect. 2013; 66: 95–102. doi: 10.1016/j.jinf.2012.10.004 PMID: 23068454

17. Sweeney R, Conroy AB, Dwyer R, Aitken CK. The economic burden to the public health system of treating non-viral injecting-related injury and disease in Australia (a cost of illness analysis). Aust N Z J Public Health. 2009; 33: 352–357. doi: 10.1111/j.1753-6405.2009.00407.x PMID: 19689596

18. Spijkerman U, van Amelorden EJ, Mientjes GH, Coutinho RA, van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol. 1996; 49: 1149–1154. PMID: 8826995

19. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Infect Dis. 2000; 30: 374–379. PMID: 10671344

20. Jain V, Yang MH, Kovacicova-Lezcano G, Juhle LS, Bolger AF, Winston LG. Infective endocarditis in an urban medical center association of individual drugs with valvular involvement. J Infect. 2008; 57: 132–138. doi: 10.1016/j.jinf.2008.05.008 PMID: 18597851

21. Saydain G, Singh-J, Dalal B, Yao W, Levine DP. Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit. J Crit Care. 2010; 25: 248–253. doi: 10.1016/j.jcrc.2009.09.007 PMID: 19906509

22. Tunkel AR, Pradhan SK. Central nervous system infections in injection drug users. Infect Dis Clin North Am. 2002; 16: 589–605. PMID: 12371117

23. Heinzinger KG, Etzioni DA, Hurley B, Holton P, Bluthenthal RN, Asch SM. Hospital utilization for injection drug use-related soft tissue infections in urban versus rural counties in California. J Urban Health. 2006; 83: 176–181. PMID: 16793676

24. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, Schechter MT, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001; 165: 415–420. PMID: 11531049
25. Stein MD, Sobota M. Injection drug users: hospital care and charges. Drug Alcohol Depend. 2001; 64: 117–120. PMID: 11470348
26. Takahashi TA, Maciejewski ML, Bradley K. US hospitalizations and costs for illicit drug users with soft tissue infections. J Behav Health Serv Res. 2010; 37: 508–518. doi: 10.1007/s11414-009-9177-z PMID: 19381818
27. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005; 40: 609–616. PMID: 16284539
28. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. Clin Infect Dis. 2007; 45: 1200–1203. PMID: 17918083
29. Micalef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One. 2014; 9: e101717. doi: 10.1371/journal.pone.0101717 PMID: 25032825
30. American Hospital Directory. Jackson Memorial Hospital Facility Profile. 2015. Available: http://www.ahd.com/free_profile/100022/Jackson_Memorial_Hospital/Miami/Florida/. Accessed 2015 Feb 18.
31. U.S. Census Bureau. Miami-Dade County QuickFacts. 2013. Available: http://quickfacts.census.gov/qfd/states/12/12086.html Accessed 2015 Feb 18.
32. Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J Stud Alcohol Drugs. 2008; 69: 924–932. PMID: 18925351
33. Chen JL, Fullerton KE, Flynn NM. Necrotizing fasciitis associated with injection drug use. Clin Infect Dis. 2001; 33: 6–15. PMID: 11389488
34. Ebright JR, Pieper B, Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am. 2002; 16: 697–712. PMID: 12371123
35. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol. 2004; 150: 1–10. PMID: 15115440
36. Kak V, Chandrasekar PH. Bone and joint infections in injection drug users. Infect Dis Clin North Am. 2002; 16: 681–695. PMID: 12371122
37. Takahashi TA, Baernstein A, Binswanger I, Bradley K, Merrill JO. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med. 2007; 22: 382–388. PMID: 18026806
38. Harris HW, Young DM. Care of injection drug users with soft tissue infections in San Francisco, California. Arch Surg. 2002; 137: 1217–1222. PMID: 12413304
39. Belani HK, Muennig PA. Cost-effectiveness of Needle and Syringe Exchange for the Prevention of HIV in New York City. J HIV/AIDS & Social Services. 2008; 7: 229.
40. Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: an economic evaluation of a local experience. CMAJ. 1997; 157: 255–262. PMID: 9269195
41. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18 Suppl 1: S133–8. PMID: 9663636
42. Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. 2012; 26: 2201–2210. doi: 10.1097/QAD.0b013e3283578b5d PMID: 22914579
43. Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J Stud Alcohol Drugs. 2008; 69: 924–932. PMID: 18925351
44. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18 Suppl 1: S133–8. PMID: 9663636
45. Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. 2012; 26: 2201–2210. doi: 10.1097/QAD.0b013e3283578b5d PMID: 22914579
46. Tooke HE, Kral AH, Wenger LD, Cardenas GA, Martinez AN, Sherman RL, et al. A comparison of syringe disposal practices among injection drug users in a city with versus a city without needle and syringe programs. Drug Alcohol Depend. 2012; 123: 255–259. doi: 10.1016/j.drugalcdep.2011.12.001 PMID: 22209091